RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Detail |
|
Starting dose
|
600 mg once daily |
|
Titration
|
Reassess blood pressure after 2–3 weeks; increase or split dose if target BP not achieved |
|
Usual maintenance dose
|
600 mg once daily (may be given as 400 mg + 200 mg or 300 mg twice daily in select patients, though commonly kept as a single daily dose) |
|
Maximum dose
|
800 mg per day (in one or two divided doses) |
|
Key clinical notes
|
• May be used as monotherapy or combined with a thiazide diuretic or calcium channel blocker for additive BP lowering • Onset of antihypertensive effect within 1–2 weeks; maximal effect by 2–3 weeks • Unlike most other ARBs, eprosartan is a non-biphenyl, non-tetrazole compound; it additionally blocks presynaptic angiotensin II receptors on sympathetic nerve terminals, providing a modest sympatholytic effect • Volume- or salt-depleted patients (e.g., those on high-dose diuretics or with restricted salt intake) should have volume corrected before initiation or start with a reduced dose of 400 mg daily • No dose adjustment needed based on gender or age alone, but clinical caution in the elderly (see Elderly section) • If switching from another ARB, eprosartan can be started the day after discontinuation of the previous agent • Not a first-line ARB in Indian practice; losartan, telmisartan, and olmesartan are far more widely prescribed and available |
| eGFR (mL/min/1.73 m²) | Recommendation |
|
≥ 50
|
No dose adjustment required; standard dosing applies |
|
30–49
|
Use with caution; monitor serum creatinine and potassium within 1–2 weeks of initiation; consider starting at 400 mg daily |
|
< 30 (not on dialysis)
|
Use only under specialist supervision; increased risk of hyperkalaemia and deterioration of renal function; start at 400 mg daily if used |
|
Haemodialysis
|
Eprosartan is not significantly removed by haemodialysis (high protein binding, predominantly biliary/faecal excretion); no supplemental dose required post-dialysis; however, use with extreme caution and specialist input |
| Child-Pugh Class | Recommendation |
|
A (Mild)
|
No dose adjustment required |
|
B (Moderate)
|
Use with caution; consider initiating at 400 mg daily; monitor liver function |
|
C (Severe)
|
Avoid use; no adequate safety data available in severe hepatic impairment |
| Parameter | Detail |
|
Overall safety
|
Contraindicated in the second and third trimesters; exposure during this period is associated with fetal renal dysgenesis, oligohydramnios, skull ossification defects, and neonatal death |
|
First trimester
|
Should be avoided; if inadvertently used, discontinue as soon as pregnancy is confirmed and switch to a safer alternative |
|
Preferred alternatives in Indian obstetric practice
|
Methyldopa (first line); labetalol; nifedipine extended-release |
|
When it may be used
|
Should not be used at any stage of pregnancy |
|
Monitoring if inadvertently exposed
|
Serial ultrasonography for amniotic fluid volume, fetal renal function, and fetal growth; neonatal assessment for hypotension, oliguria, and hyperkalaemia |
| Parameter | Detail |
|
Compatibility with breastfeeding
|
Not recommended; it is unknown whether eprosartan is excreted in human breast milk (it is excreted in the milk of lactating rats) |
|
Expected drug levels in milk
|
Unknown in humans |
|
Preferred alternatives
|
Labetalol, nifedipine, or enalapril (all have more established breastfeeding safety data) |
|
Monitoring in infant
|
If exposure occurs, monitor infant for hypotension (lethargy, poor feeding), reduced urine output, and poor weight gain |
| Interacting Drug/Class | Effect / Mechanism | Action |
|
Aliskiren (in diabetic or renally impaired patients)
|
Dual RAAS blockade → increased risk of hyperkalaemia, hypotension, and acute kidney injury | Contraindicated in combination in patients with diabetes or eGFR < 60 |
|
ACE inhibitors (e.g., enalapril, ramipril)
|
Dual RAAS blockade → same risks as above | Avoid concurrent use; if unavoidable, specialist supervision and close monitoring mandatory |
|
Potassium-sparing diuretics (spironolactone, eplerenone, amiloride)
|
Additive hyperkalaemia risk | Monitor serum potassium within 1 week of combination and regularly thereafter; avoid if baseline K⁺ > 5.0 mEq/L |
|
Potassium supplements
|
Additive hyperkalaemia risk | Use only if documented hypokalaemia; monitor potassium closely |
|
Lithium
|
ARBs reduce lithium renal clearance → increased serum lithium levels and toxicity risk | Monitor lithium levels frequently if combination is unavoidable; consider alternative antihypertensive |
|
NSAIDs (including COX-2 selective inhibitors)
|
Blunting of antihypertensive effect; increased risk of acute kidney injury and hyperkalaemia, particularly in volume-depleted or elderly patients | Avoid prolonged concurrent use; if short-term NSAID use is needed, monitor renal function and blood pressure |
| Interacting Drug/Class | Effect | Action |
|
Thiazide or loop diuretics
|
Enhanced hypotensive effect, especially in volume-depleted patients | Ensure adequate hydration before initiating eprosartan; monitor blood pressure after starting combination |
|
Antidiabetic agents (insulin, sulfonylureas)
|
ARBs may modestly improve insulin sensitivity; risk of hypoglycaemia when combined with antidiabetic drugs | Monitor blood glucose more frequently after initiation; dose adjustment of antidiabetic may be needed |
|
Trimethoprim / co-trimoxazole
|
Trimethoprim has potassium-sparing effect → additive hyperkalaemia risk with ARBs | Check serum potassium during concurrent use, especially in elderly or renally impaired patients |
|
Heparin (including LMWH)
|
Additive hyperkalaemia risk | Monitor potassium during concurrent use |
| Timing | Parameters |
|
Baseline (before initiation)
|
Blood pressure, serum creatinine, eGFR, serum potassium, sodium; assess volume status |
|
1–2 weeks after initiation or dose change
|
Blood pressure, serum creatinine, eGFR, serum potassium |
|
Long-term (every 3–6 months for stable patients)
|
Blood pressure, renal function (creatinine, eGFR), serum electrolytes (potassium, sodium) |
|
Situational
|
Recheck renal function and potassium if intercurrent illness (diarrhoea, vomiting, fever), addition of interacting drug (NSAID, diuretic, potassium-sparing agent), or symptoms of hypotension develop |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.